Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia ... Nearly all children with ANCA-associated vasculitis demonstrate active kidney disease at diagnosis, and ...

Giant cell arteritis (GCA) is the most common form of vasculitis in the older adult population. There are variable clinical presentations of this entity and no perfect diagnostic test, often ...

Alaska Native and American Indian adults have a high prevalence of AAV, with distinct clinical characteristics and treatment patterns observed.

Patients with LVV and IBD present with distinct clinical characteristics, including earlier onset and more severe vascular involvement.

A person may also experience: In the next phase, the person typically has eosinophilia, a condition when there are too many eosinophils, a type of white blood cell. The third phase is vasculitis ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

Studies of patients with PMR and giant-cell arteritis indicate that PMR could be a vasculitis limited to the subclavian or axillary arteries, or a synovitis or perisynovitis of the shoulders and hips.

Giant cell arteritis is a systemic vasculitis and careful attention should be given to the examination of the cardiovascular system including performing blood pressure measurements in both arms.

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...